The Technical Analyst
HOOKIPA Pharma Inc [HOOK]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
HOOKIPA Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-3.91% $0.735
America/New_York / 19 apr 2024 @ 15:40
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 70.96 mill |
| EPS: | -0.860 |
| P/E: | -0.850 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 96.55 mill |
| Avg Daily Volume: | 0.543 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.850 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.14x |
| Company: PE -0.850 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.704 - 0.794 ( +/- 6.01%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Orlinger Klaus | Buy | 367 300 | Stock Option (Right to Buy) |
| 2024-04-15 | Aldag Jorn | Buy | 971 400 | Stock Option (Right to Buy) |
| 2024-04-15 | Winderlich Mark | Buy | 250 000 | Stock Option (Right to Buy) |
| 2024-04-15 | Winderlich Mark | Buy | 50 000 | Stock Option (Right to Buy) |
| 2024-04-15 | Kandera Reinhard | Buy | 406 200 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 98.81 |
| Last 94 transactions |
| Buy: 7 455 375 | Sell: 565 370 |
Forecast:
16:00 - $0.740
Live Trading Signals (every 1 min)
Forecast
1: 15:54 - $0.740
Forecast 2: 16:00 - $0.740
Forecast 3: 16:00 - $0.740
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.735 (-3.91% ) |
| Volume | 0.381 mill |
| Avg. Vol. | 0.543 mill |
| % of Avg. Vol | 70.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HOOK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $0.661 | N/A | Active |
|---|
HOOK
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Latest Press Releases
2024-04-16 16:30:00 - Press Release
Hookipa Pharma Announces Grant Of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
New york and vienna, austria, april 16, 2024 (globe newswire) -- hookipa pharma inc. (nasdaq: hook, ‘hookipa'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the compensation committee of the company's board of directors approved the grant of non-statutory options to mark winderlich, who was appointed chief development officer of the company effective april 1, 2024, to purchase an aggregate of 250,000 shares of the company's common stock under hookipa's 2023 inducement plan. the award was granted as an inducement material to the employee's acceptance of employment with hookipa in accordance with nasdaq listing rule 5635(c)(4)...
2024-04-10 07:01:00 - Press Release
Hookipa Pharma To Host Investor Call On Hb-200 And Planned Path To Registration
New york and vienna, austria, april 10, 2024 (globe newswire) -- hookipa pharma inc. (nasdaq: hook, hookipa or the company), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of hookipa's executive team will host an investor call summarizing the company's constructive regulatory interactions with the u.s. food & drug administration (fda) and the european medicines agency (ema). hookipa and the fda have aligned on the design and protocol of the company's upcoming pivotal phase 2/3 clinical trial of hb-200 in combination with pembrolizumab. the investor call will be held on april 25, 2024, at 8:00 a.m. et. complete details and registration information are included below.
2024-03-22 07:01:00 - Press Release
Hookipa Pharma Reports Fourth Quarter And Full Year 2023 Financial Results And Recent Business Highlights
New york and vienna, austria, march 22, 2024 (globe newswire) -- hookipa pharma inc. (nasdaq: hook, ‘hookipa'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the fourth quarter and full year 2023.
2024-03-06 07:01:00 - Press Release
Hookipa Pharma To Participate In Leerink Partners Global Biopharma Conference
New york and vienna, austria, march 06, 2024 (globe newswire) -- hookipa pharma inc. (nasdaq: hook, ‘hookipa'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that hookipa's chief financial officer, reinhard kandera, will present at the leerink partners global biopharma conference on march 13, 2024. webcast details are available below.
2024-01-29 08:01:00 - Press Release
Hookipa Pharma Provides Update On Business Priorities And Oncology Partnership Programs
New york and vienna, austria, jan. 29, 2024 (globe newswire) -- hookipa pharma inc. (nasdaq: hook, ‘hookipa'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will focus its resources in two strategic areas: (1) prioritize the clinical development of a randomized trial for its hb-200 program in human papillomavirus 16 positive (hpv16+) head and neck squamous cell carcinoma (hnscc) and (2) its two gilead-partnered infectious disease cure programs for hepatitis b and human immunodeficiency virus.
Latest News
2024-03-22 09:16:03 - Zacks Investment Research
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
HOOKIPA Pharma Inc. (HOOK) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.17 per share a year ago.
2024-02-02 13:01:09 - Zacks Investment Research
All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy
HOOKIPA Pharma Inc. (HOOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2024-02-02 11:01:19 - Zacks Investment Research
Best Momentum Stocks to Buy for February 2nd
BK, HCA and HOOK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 2, 2023.
2023-12-21 09:15:27 - InvestorPlace
Why Is Hookipa Pharma (HOOK) Stock Up 81% Today?
Hookipa Pharma (NASDAQ: HOOK ) stock is on the rise Thursday as investors react to news of a share purchase agreement with Gilead Sciences (NASDAQ: GILD ). According to a filing with the Securities and Exchange Commission (SEC), Gilead Sciences has bought another 15 million shares of HOOK stock for $1.4167 per share.
2023-11-20 10:17:26 - PennyStocks
Best Penny Stocks To Buy This Week? 4 To Watch Now
Whether you're looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week with Thursday's Thanksgiving Holiday and one of the “Magnificent Seven” could become a major catalyst.
2023-11-02 16:01:00 - GlobeNewsWire
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023.
2023-09-06 20:17:22 - InvestorPlace
7 Biotech Stocks to Sell in September Before They Crash & Burn
Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.
2023-09-06 07:01:00 - GlobeNewsWire
HOOKIPA Pharma to participate in upcoming investor conferences in September
NEW YORK and VIENNA, Austria, Sept. 06, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate in and present at the following upcoming investor conferences:
2023-08-03 07:01:00 - GlobeNewsWire
HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023
NEW YORK and VIENNA, Austria, Aug. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its second quarter 2023 financial results and business highlights on August 10, 2023.
2023-05-31 19:47:53 - PennyStocks
Stock Market Today: New Penny Stocks Trends & 3 To Watch This Week
This week has seen the stock market flip-flop, including the volatile world of penny stocks. Investors, especially those interested in high-risk, high-reward low-priced stocks, are attentively tracking the developments in Washington.